Treatment and Prognosis of Primary Gastric B-cell Lymphoma―Special Reference to Therapeutic Strategy for MALT Lymphoma Shotaro Nakamura 1 , Takayuki Matsumoto 1 , Shigeo Nakamura 1 1Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University Keyword: 胃リンパ腫 , MALT リンパ腫 , Helicobacter pylori , 化学療法 , 放射線療法 pp.261-275
Published Date 2004/3/25
DOI https://doi.org/10.11477/mf.1403100437
  • Abstract
  • Look Inside
  • Reference
  • Cited by

 To evaluate the influence of therapeutic methods on the prognosis of primary gastric B-cell lymphoma, we analyzed the prognostic factors for 322 patients, comprised of 186 with low-grade MALT lymphoma,54 with diffuse large B-cell lymphoma (DLBL)plus MALT lymphoma, and 82 with DLBL without MALT lymphoma. Among them, the clinical course of 96 patients who were treated by Helicobacter pylori eradication was also evaluated. Patients who underwent stomach-conserving treatment(H. pylori eradication, chemotherapy or radiation ; n=100)showed a better overall survival probability than those treated by surgery(n=222), but the progression-free probability did not differ between the two groups. After H. pylori eradication, complete remission was achieved in 55 patients, of whom histologic relapse was observed in 4 patients(7 %). Second line treatment for 34 patients, who failed to respond to eradication therapy, including oral monochemotherapy with cyclophosphamide, radiation,CHOP chemotherapy, and gastrectomy resulted in complete remission in 29 patients(85 %). These results suggest stomach-conserving treatment to be an optimal therapeutic modality for primary gastric B-cell lymphoma.

 1) Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Copyright © 2004, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1219 印刷版ISSN 0536-2180 医学書院